Predictive Biosciences announced a partnership with ARUP Laboratories that will offer the company’s molecular diagnostic bladder cancer tests to ARUP’s national network of clients.
Lexington-based Predictive Biosciences specializes in molecular diagnostic cancer assays and provides molecular pathology services for urologists.
Under a non-exclusive agreement, ARUP, a lab at the University of Utah, will offer Predictive’s CertNDx Bladder Cancer Assays in its comprehensive test menu to hospitals, health care providers, academic medical centers, and military and government facilities around the country, the company said in a press release.
In a statement, Predictive Biosciences chief executive Pierre Cassigneul said: “We are excited to begin our partnership with ARUP, a laboratory that shares our passion for innovation and technology. We believe this alliance will greatly expand the availability of our bladder cancer products to a wider network of leading medical facilities that can benefit from CertNDx testing.”
The CertNDx Bladder Cancer Assay is a non-invasive, urine-based test to assess patients with hematuria and to monitor for bladder cancer recurrence following treatment.
ARUP Laboratories is a national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology.